About StemSource
StemSource is a company based in Thousand Oaks (United States) founded in 2000 was acquired by Bionity in October 2002. StemSource operates in a competitive market with competitors including StemCyte, China Cord Blood, Generate, LaCell and Forever Labs, among others.
- Headquarter Thousand Oaks, United States
- SectorsHealthcare
- Website stemsource.com
- Social LinkedIn
- Acquired by Bionity (Oct 2002)
- Investors
- Acquired byBionity
(Oct 2002)
Investors in StemSource
StemSource has secured backing from 1 investor. Prominent investors backing the company include bionity.com.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Information on life sciences, biotechnology, and pharma is offered online. | 2000 | bionity.com | Berlin, Germany |
Investor details for StemSource
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of StemSource
1 people are tracked at StemSource (1 in leadership).
| Name | Role | Group |
|---|---|---|
Marc Hedrick | CEO & President | Leadership |
Complete people profiles for StemSource
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of StemSource
2 dated milestones of StemSource across 2 years, from founding to its latest funding, stage changes and deals.
- Founded StemSource is founded.
- Exit Acquired by Bionity.
Competitors of StemSource
StemSource operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as StemCyte, China Cord Blood, Generate, LaCell and Forever Labs, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| stemcyte.com | 1997 | Covina, United States | $23.25M | 43 | Umbilical cord blood stem cell transplantation and therapeutic products company | |
| globalcordbloodcorp.com | 2003 | Hong Kong, China | – | – | Biobanking services for umbilical cord blood stem cells are provided. | |
| generate.com | 1977 | Los Angeles, United States | – | – | Provider of services for the storage of stem cells | |
| lacell-usa.com | 2010 | New Orleans, United States | – | – | Stem Cell Production | |
| foreverlabs.com | 2015 | Detroit, United States | $2.22M | 9 | Stem cells are stored and preserved for future therapeutic applications. | |
| provialabs.com | 2009 | Littleton, United States | $1M | 15 | Stem cell biobanking and manufacturing from children's teeth are provided. | |
| millcreekls.com | 2010 | Rochester, United States | $625,000 | – | Tools and technologies to support the development and application of cellular and biologic therapeutics |
Detailed competitors of StemSource
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to StemSource
10 companies that operate in the same segment as StemSource (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about StemSource
StemSource was founded in 2000.
StemSource is headquartered in Thousand Oaks, United States. It is registered at Thousand Oaks, California, United States.
Marc Hedrick is the current CEO of StemSource.
StemSource was established in 2000 in Thousand Oaks, United States, within the biobanking and regenerative medicine sector. Operations center on the collection and preservation of stem and regenerative cells from adipose tissue, recognized as a primary source. A minor liposuction procedure is utilized to harvest these cells, enabling their storage for potential therapeutic uses in medical applications.
StemSource's top competitors include StemCyte, Forever Labs and China Cord Blood.
StemSource has 1 investor. Key investors include bionity.com.
Yes. StemSource was acquired by Bionity in October 2002.